|
|
 Previous Article | Table of Contents | Next Article 
Interleukin-6 is a potent thrombopoietic factor in vivo in mice
T Ishibashi, H Kimura, Y Shikama, T Uchida, S Kariyone, T Hirano, T Kishimoto, F Takatsuki and Y Akiyama
First Department of Internal Medicine, Fukushima Medical College, Japan.
To determine the biologic activity of interleukin-6 (IL-6) on
megakaryocytopoiesis and thrombocytopoiesis in vivo, the cytokine was
administered intraperitoneally to mice every 12 hours at varying doses for
five days or for varying time intervals, based on the kinetic analysis of
IL-6 serum levels indicating the peak of 40 minutes following injection,
with no detection at 150 minutes. A dose-response experiment showed that
IL-6 increased platelet counts in a dose- dependent fashion at a plateau
stimulation level of 5 micrograms. Administration of 5 micrograms of IL-6
reproducibly elevated platelet counts at five days by approximately 50% to
60% of increase. Moreover, a striking increase in megakaryocytic size in
response to IL-6 was elicited by the treatment, but no change in
megakaryocyte numbers; whereas IL-6 administration did not expand CFU-MK
numbers. The in vivo studies in this manner had negligible effects on other
hematologic parameters, with the minor exception of monocyte levels. These
data show that IL-6 acts on maturational stages in megakaryocytopoiesis and
promotes platelet production in vivo in mice, suggesting that IL-6
functions as thrombopoietin.
Volume 74,
Issue 4,
pp. 1241-1244,
09/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. L. Angiolillo, V. Davenport, M. A. Bonilla, C. van de Ven, J. Ayello, O. Militano, L. L. Miller, M. Krailo, G. Reaman, and M. S. Cairo
A Phase I Clinical, Pharmacologic, and Biologic Study of Thrombopoietin and Granulocyte Colony-Stimulating Factor in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Recurrent or Refractory Solid Tumors: A Children's Oncology Group Experience
Clin. Cancer Res.,
April 1, 2005;
11(7):
2644 - 2650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurzrock
Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited
Clin. Cancer Res.,
February 15, 2005;
11(4):
1361 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tanaka, Y. Hirabayashi, T. Sekiguchi, T. Inoue, M. Katsuki, and A. Miyajima
Targeted disruption of oncostatin M receptor results in altered hematopoiesis
Blood,
November 1, 2003;
102(9):
3154 - 3162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Hitchcock, T. M. Skerry, M. R. Howard, and P. G. Genever
NMDA receptor-mediated regulation of human megakaryocytopoiesis
Blood,
August 15, 2003;
102(4):
1254 - 1259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kaser, G. Brandacher, W. Steurer, S. Kaser, F. A. Offner, H. Zoller, I. Theurl, W. Widder, C. Molnar, O. Ludwiczek, et al.
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
Blood,
November 1, 2001;
98(9):
2720 - 2725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. V. Denis, K. Kwack, S. Saffaripour, S. Maganti, P. Andre, R. G. Schaub, and D. D. Wagner
Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models
Blood,
January 15, 2001;
97(2):
465 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bracho, M. D. Krailo, V. Shen, S. Bergeron, V. Davenport, W. Liu-Mares, B. R. Blazar, A. Panoskaltsis-Mortari, C. van de Ven, R. Secola, et al.
A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities
Clin. Cancer Res.,
January 1, 2001;
7(1):
58 - 67.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Nishimoto, T. Kishimoto, and K. Yoshizaki
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
Ann Rheum Dis,
November 1, 2000;
59(90001):
i21 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gainsford, H. Nandurkar, D. Metcalf, L. Robb, C. G. Begley, and W. S. Alexander
The residual megakaryocyte and platelet production in c-Mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor
Blood,
January 15, 2000;
95(2):
528 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Senaldi, B. C. Varnum, U. Sarmiento, C. Starnes, J. Lile, S. Scully, J. Guo, G. Elliott, J. McNinch, C. L. Shaklee, et al.
Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family
PNAS,
September 28, 1999;
96(20):
11458 - 11463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sasaki, T. Takahashi, H. Miyazaki, A. Matsumoto, T. Kato, K. Nakamura, S. Iho, Y. Okuno, and K. Nakao
Production of Thrombopoietin by Human Carcinomas and Its Novel Isoforms
Blood,
September 15, 1999;
94(6):
1952 - 1960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Agnello, C. Meazza, C. G. Rowan, P. Villa, P. Ghezzi, and G. Senaldi
Leptin causes body weight loss in the absence of in vivo activities typical of cytokines of the IL-6 family
Am J Physiol Regulatory Integrative Comp Physiol,
September 1, 1998;
275(3):
R913 - R919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ishida, T. Ito, and S.-i. Kuriya
Effects of C-Mpl Ligand on Cytoplasmic Maturation of Murine Megakaryocytes and on Platelet Production
J. Histochem. Cytochem.,
January 1, 1998;
46(1):
49 - 58.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. O'Malley, P. Langhorne, R.A. Elton, and C. Stewart
Platelet Size in Stroke Patients
Stroke,
June 1, 1995;
26(6):
995 - 999.
[Abstract]
[Full Text]
|
|
|
|
|
